Published in Vaccine Weekly, November 24th, 2010
Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide.
Vaccination of the first study group has been completed and demonstrated that
PEV7 is safe and well-tolerated in all subjects and elicits an immune response even at low doses.
"This is an important step for both PEV7 and Pevion as we aim for proof of concept in humans with our innovative approach to disease management using a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly